Florida Cancer Specialists Leads Policy and Innovation Discussions at 2026 PCOC Conference

  • Florida Cancer Specialists (FCS) presented insights from the 2026 J&J Oncology Care Index at the Patient-Centered Oncology Care conference on September 24, 2026.
  • FCS conducts over 180 active clinical trials annually, positioning it as a leader in oncology research among private practices.
  • Key FCS executives participated in panels discussing policy, innovation, and patient access in oncology care.
  • FCS highlighted the role of AI, clinical trial access, and precision oncology in shaping future cancer care.

Florida Cancer Specialists is positioning itself as a key influencer in oncology policy and innovation, leveraging its extensive clinical trial program and community-based care model. The 2026 PCOC conference discussions highlight the growing importance of AI, precision oncology, and patient-centered care in reshaping the oncology landscape. FCS's role in these conversations underscores its strategic position as a leader in community-based cancer care and research.

Policy Influence
How FCS's insights from the J&J Oncology Care Index will shape future cancer care policy.
Innovation Adoption
The pace at which emerging therapies and AI are integrated into real-world oncology practice.
Clinical Trial Access
Whether FCS can sustain its leadership in expanding patient access to cutting-edge clinical trials.